Hormonal Changes After 50: Menopause, Andropause, and Your Health
Hormonal shifts after 50 affect virtually every system in the body — metabolism, sleep, mood, bone density, cardiovascular health, cognitive function, and sexual health. Understanding these changes demystifies the symptoms you may experience and opens the door to evidence-based interventions that can dramatically improve quality of life during and after this transition.
Written by
Dr. Sarah Chen, MD
Preventive Medicine
Medically reviewed by
Dr. Michael Chen, MD
Board-Certified Endocrinologist
More in Health After 50
View allHealth After 50
Health After 50: Your Complete Guide to Thriving in Midlife and Beyond
15 min read
Health After 50
The Most Common Diseases After 50 — and How to Protect Yourself
13 min read
Health After 50
Cancer Prevention After 50: Screenings, Lifestyle Changes, and Risk Reduction
12 min read
Health After 50
Heart Health After 50: Protecting Your Cardiovascular System
12 min read
Health After 50
Osteoporosis After 50: Building and Protecting Your Bone Density
11 min read
Health After 50
Brain Health After 50: Stay Sharp and Prevent Cognitive Decline
13 min read
Health After 50
Exercise After 50: The Ultimate Guide to Safe and Effective Fitness
14 min read
Health After 50
Sleep After 50: Why It Changes and How to Sleep Better
11 min read
Health After 50
Nutrition After 50: What to Eat for Longevity and Vitality
13 min read
Key Takeaways
- Menopause affects 75% of women with hot flashes — modern hormone therapy is highly effective and safer than previously feared when started early
- Transdermal estrogen has a significantly safer cardiovascular and clot risk profile than oral estrogen tablets
- Low testosterone affects 20–40% of men over 60 — TSH testing at 50+ can catch treatable hypothyroidism
- Non-hormonal options (SSRIs, fezolinetant, CBT-M) are effective alternatives for women who cannot use hormone therapy
- Annual thyroid (TSH) testing is recommended for all women over 50
In This Article
Menopause: What Is Actually Happening
Menopause is defined as 12 consecutive months without a menstrual period, typically occurring at an average age of 51 in the United States. The perimenopausal transition — which averages 4–7 years in duration — is often the most symptomatic phase, characterized by erratic estrogen fluctuations as the ovaries' follicle supply depletes. The primary symptom of menopause — the vasomotor symptoms (hot flashes and night sweats) — affects approximately 75% of women and is caused by estrogen's role in regulating the hypothalamic thermostat. Other common symptoms include sleep disruption, mood changes, vaginal dryness and genitourinary symptoms (affecting long-term sexual health and urinary function), joint pain, cognitive changes ('brain fog'), and skin and hair changes. The decline in estrogen also initiates the cardiovascular risk surge and accelerated bone loss discussed elsewhere in this series.
Hormone Therapy: Benefits, Risks, and Who It's For
Menopausal hormone therapy (MHT, formerly called HRT) is the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause. The 2002 Women's Health Initiative (WHI) trial initially raised concerns about breast cancer and cardiovascular risk, leading to a dramatic drop in HRT prescribing. Subsequent reanalysis and updated guidelines have substantially revised this picture: for healthy women under 60 or within 10 years of menopause onset, the benefits of hormone therapy typically outweigh the risks. Transdermal (patch, gel, spray) estrogen has a significantly safer cardiovascular and clot risk profile than oral estrogen. The addition of progesterone is necessary for women with a uterus (to prevent endometrial cancer), but micronized progesterone (Prometrium) has a more favorable profile than synthetic progestins. For women with intact uterus, local vaginal estrogen for genitourinary symptoms has minimal systemic absorption and no significant systemic risk. Women with a history of breast cancer, blood clots, or active cardiovascular disease are generally not candidates for systemic MHT.
Andropause: The Male Hormonal Shift
Unlike menopause, testosterone decline in men is gradual — approximately 1–2% per year from age 30 onward, with clinically significant testosterone deficiency affecting approximately 20–40% of men over 60 (by various definitions). Symptoms of low testosterone (hypogonadism) include decreased energy, reduced libido, erectile dysfunction, decreased muscle mass and strength, increased body fat, mood changes and depression, cognitive changes, decreased bone density, and sleep disturbances. Many of these symptoms are nonspecific and overlap with other conditions, making diagnosis dependent on a combination of symptoms and confirmed low serum testosterone levels on at least two morning measurements. It is important to distinguish primary hypogonadism (testicular failure) from secondary (pituitary or hypothalamic dysfunction), as the distinction affects treatment and may reveal underlying conditions.
Testosterone Therapy in Men: Evidence and Considerations
Testosterone replacement therapy (TRT) in men with confirmed hypogonadism produces consistent improvements in sexual function, energy, mood, muscle mass, and bone density. The landmark Testosterone Trial (TTrials) — 7 coordinated trials in 790 symptomatic hypogonadal men — found significant improvements in sexual function, vitality, and mood with TRT compared to placebo. The TRAVERSE trial (2023) found no significant increase in major cardiovascular events with TRT, addressing a longstanding safety concern. However, TRT is not without risks: it can suppress natural testosterone production and fertility (men desiring fertility should not use TRT), can cause polycythemia (increased red blood cell count), and can stimulate prostate growth. Regular monitoring of PSA, hematocrit, and symptoms is essential during TRT. Available forms include daily topical gels, weekly or biweekly injections, pellet implants, and buccal patches.
Thyroid Health After 50
Thyroid dysfunction becomes increasingly common after 50, particularly in women. Hypothyroidism (underactive thyroid) affects approximately 10% of women over 60 and is frequently missed because its symptoms — fatigue, weight gain, constipation, cold intolerance, cognitive slowing, dry skin, and hair loss — are easily attributed to normal aging. Thyroid-stimulating hormone (TSH) testing is the standard screen and should be performed as part of routine health checks after 50. Subclinical hypothyroidism (elevated TSH with normal T4) is particularly common and its treatment remains debated; treatment decisions are individualized based on symptoms, TSH levels, and overall health. Hyperthyroidism (overactive thyroid) — most commonly due to Graves' disease or toxic nodular goiter — causes weight loss, palpitations, heat intolerance, anxiety, and osteoporosis and becomes more common with age. Annual TSH testing is a reasonable approach for most adults over 50, especially women.
Managing Symptoms With Lifestyle and Non-Hormonal Options
For women who cannot or choose not to use hormone therapy, several non-hormonal approaches have evidence for managing menopausal symptoms. Cognitive behavioral therapy for menopause (CBT-M) has shown significant reductions in hot flash frequency and their impact on quality of life. Clinical hypnosis reduced hot flash frequency by 74% in one clinical trial. SSRIs/SNRIs (particularly escitalopram, paroxetine, and venlafaxine) reduce hot flash frequency by 40–60%. Gabapentin and pregabalin are effective for refractory vasomotor symptoms and sleep disruption. Fezolinetant, a neurokinin receptor antagonist approved in 2023, specifically targets the hypothalamic pathway causing hot flashes with no hormonal activity. Phytoestrogens (plant estrogens) like soy isoflavones have modest, inconsistent evidence for hot flash reduction. Exercise significantly improves vasomotor symptoms, mood, sleep, and bone health — making it a cornerstone of nonpharmacological menopause management.
